NASDAQ · Biotechnology

CytoMed Therapeutics Limited (GDTC) Stock

$0.89 -5.81% NASDAQ: GDTC Healthcare

Valuation

MetricValue
Price$0.89
Market Cap$10.53M
P/E Ratio-2.56
P/B Ratio2.81
P/S Ratio20.92
EPS (TTM)$-0.33
52-Week High$3.68
52-Week Low$0.68
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-87.20%
ROA-78.47%
ROCE-98.10%
Gross Margin-63.95%
Operating Margin-10.75%
Net Margin-826.34%
Debt/Equity0.09
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$0$0
Operating Profit$-1.0M$-2.0M$-2.0M$-3.0M$-5.0M
Net Profit$-2.0M$-3.0M$-4.0M$-3.0M$-4.0M
EPS$-0.30$-0.40$-0.38$-0.22$-0.33
Op Margin—-624.5%-310.2%-4504.3%-1416.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.0M$5.0M$12.0M$10.0M$8.0M
Total Liabilities$3.0M$5.0M$1.0M$1.0M$1.0M
Cash$3.0M$2.0M$9.0M$5.0M$2.0M
Borrowings$3.0M$4.0M$0$0$0

Latest News

CytoMed Therapeutics Gets Nasdaq Minimum Bid Price Deficiency Notice MT Newswires · Oct 9, 2026 CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency GlobeNewswire · Oct 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-1.0M$-4.0M$-3.0M$-4.0M
Investing Cash Flow$-1.0M$-1.0M$-3.0M$0$0
Financing Cash Flow$0$1.0M$11.0M$0$0
Net Cash Flow$2.0M$-1.0M$5.0M$-2.0M$-3.0M
Free Cash Flow$-2.0M$-2.0M$-4.0M$-4.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.50
EV / EBITDA-2.11
FCF Yield-51.74%
Quick Ratio2.64
Interest Coverage-221.99
Return 1Y-50.00%
Return 3Y-76.50%
Return 5Y—

Ownership

Insiders Held68.78%
Institutions Held0.18%
Institutions Float Held0.57%
Institutional HolderSharesReport Date
Xtx Topco Ltd10,1362026-03-31
UBS Group AG6,1822026-03-31
Osaic Holdings Inc.212026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGNCollPlant Biotechnologies Ltd. $3.51 -11.59% -0.37 $4.55M 0.00%
ENLVEnlivex Ltd. $0.25 -8.30% 0.03 $4.28M 0.00%
LSTALisata Therapeutics, Inc. $1.06 -11.67% -0.90 $9.65M 0.00%
MTVAMetaVia Inc. $1.41 +5.22% -0.38 $9.29M 0.00%
NCNANuCana plc $1.35 +3.05% -0.14 $8.20M 0.00%

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited is led by CEO Chee Kong Choo, employs 43 people, headquartered in SG, publicly traded since 2023.

CytoMed Therapeutics Limited (GDTC) stock trades at $0.89 with a market capitalization of $10.53M. The stock is valued at a price-to-earnings (P/E) ratio of -2.56, price-to-book of 2.81, price-to-sales of 20.92. Over the past 52 weeks the stock has ranged between $0.68 and $3.68, and currently trades 75.8% below its 52-week high.

On profitability, CytoMed Therapeutics Limited generates a return on equity (ROE) of -87.20%, return on capital employed of -98.10%, an operating margin of -10.75%, a net profit margin of -826.34%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides